Weight loss at maximum dose
No direct head-to-head trial between injection and pill. Tirzepatide from a 72-week trial; oral semaglutide from a 68-week trial.
Monthly cost self-pay
The oral pill is dramatically cheaper. With insurance, both are typically ~$25/month.
A head-to-head trial exists — but not for these two. SURMOUNT-5 compared tirzepatide injection with semaglutide injection (not the pill). Tirzepatide produced 20.2% vs 13.7% for the injection. No trial directly compares tirzepatide injection with oral semaglutide pill.
Side effects comparison
From each drug's main weight loss trial. All stomach side effects are most common in the first 4–8 weeks and usually fade.
Beyond weight loss
Form
- Tirzepatide — Once-weekly injection under the skin — no food timing restrictions
- Oral semaglutide — Once-daily pill — requires 30-min fast before eating, no injection needed
Heart benefit
- Semaglutide — 20% reduction in major heart events — proven in SELECT trial (17,604 adults)
- Tirzepatide — Heart safety confirmed — benefit trial in progress
Side effects
- Nausea (tirzepatide)~31%
- Nausea (oral semaglutide)~44%
- Quit due to side effects~7%
Usually peaks weeks 2–4, fades by week 8–12
The injection-vs-pill decision
The decision hinges on needle comfort, budget, and weight loss targets. Tirzepatide produces more weight loss through a dual-hormone mechanism, but requires weekly injections and costs roughly twice as much self-pay at the entry dose. Oral semaglutide is affordable (from $149/month), has proven heart protection, and avoids injections — but needs a 30-minute daily fast. Many people start with the pill and switch to the injection after 3–6 months if they want more weight loss.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical evidence — tirzepatide injection vs the Wegovy pill
- SURMOUNT-1 — Tirzepatide: 2,539 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2022. View source ↗
- SURMOUNT-5 — Tirzepatide: Adults with obesity or overweight, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2025. View source ↗
- OASIS 4 — Semaglutide (oral pill): 307 adults with obesity or overweight + at least 1 health condition, 64 weeks. New England Journal of Medicine, 2024. View source ↗
- SELECT — Semaglutide (injection): 17,604 adults with established cardiovascular disease and overweight or obesity (BMI 27 or higher), without type 2 diabetes, ~40 months (median). New England Journal of Medicine, 2023. View source ↗
Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: